Mymd Pharmaceuticals (NASDAQ:QCLS) Posts Quarterly Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) released its quarterly earnings results on Friday. The company reported ($0.19) earnings per share for the quarter, Zacks reports.

Mymd Pharmaceuticals Price Performance

Mymd Pharmaceuticals stock traded down $0.80 during mid-day trading on Friday, hitting $4.33. The company had a trading volume of 612,859 shares, compared to its average volume of 571,102. Mymd Pharmaceuticals has a 12 month low of $2.50 and a 12 month high of $33.56.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings began coverage on Mymd Pharmaceuticals in a research report on Wednesday. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.